News BioAtla, Inc.

Equities

BCAB

US09077B1044

Real-time Estimate Cboe BZX Other stock markets 09:45:53 2024-04-19 am EDT			5-day change	1st Jan Change
2.47 ^USD	+1.65%		-22.68%	-1.63%

Mar. 27	HC Wainwright Adjusts BioAtla's Price Target to $7 From $10, Maintains Buy Rating	MT
Mar. 26	Transcript : BioAtla, Inc., Q4 2023 Earnings Call, Mar 26, 2024

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

HC Wainwright Adjusts BioAtla's Price Target to $7 From $10, Maintains Buy Rating	Mar. 27	MT
Transcript : BioAtla, Inc., Q4 2023 Earnings Call, Mar 26, 2024	Mar. 26
BioAtla Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Progress	Mar. 26	AQ
BioAtla, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Mar. 26	CI
BioAtla to Announce Fourth Quarter and Full-Year 2023 Financial Results and Provide Business Highlights on March 26, 2024	Mar. 19	AQ
BioAtla Announces Poster Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting	Mar. 07	AQ
Transcript : BioAtla, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-11-2024 09:45 AM	Jan. 11
Sector Update: Health Care Stocks Rise in Late Afternoon Trading	Dec. 21	MT
Sector Update: Health Care Stocks Advance in Afternoon Trading	Dec. 21	MT
BioAtla Rallies After CEO Buys 50,000 Shares	Dec. 21	MT
BioAtla to Participate in the 42nd Annual J.P. Morgan Healthcare Conference	Dec. 20	GL
Transcript : BioAtla, Inc. - Special Call	Dec. 17
BioAtla, Inc.(NasdaqGM:BCAB) dropped from NASDAQ Biotechnology Index	Dec. 15	CI
BioAtla Hosting Virtual R&D Day to Highlight BA3071 CAB-CTLA-4 Phase 1 Data in Multiple Solid Tumor Types	Dec. 13	AQ
Bioatla Hosting Virtual R&D Day to Highlight Ba3071 Cab-Ctla-4 Phase 1 Data in Multiple Solid Tumor Types	Dec. 13	CI
Transcript : BioAtla, Inc. - Special Call	Dec. 13
BioAtla to Host Virtual R&D Day to Review BA3071 CAB-CTLA-4 Phase 1 Data in Multiple Solid Tumor Types on Wednesday, December 13, 2023	Dec. 06	AQ
Sector Update: Health Care Stocks Slipping Tuesday Afternoon	Dec. 05	MT
BioAtla Says Clinical Benefits, Safety Profile Support Further Evaluation of Potential Lung Cancer Therapy	Dec. 05	MT
BioAtla Presented Phase 2 Clinical Trial Data at the IASLC 2023 North America Conference on Lung Cancer and Virtual KOL Event	Dec. 05	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News BioAtla, Inc.

Equities

BCAB

US09077B1044

Summary

Filters